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Abstract 14 
Dried blood spot (DBS) sampling was investigated as a means of obtaining micro-volume blood 15 
samples for the quantitative analyses of ten commonly UK prescribed cardiovascular drugs as an 16 
indicator of medication adherence. An 8 mm disc was punched out from each DBS from calibration, 17 
quality control and volunteer samples and extracted using methanol containing the internal 18 
standard. Each extract was evaporated to dryness, the residue reconstituted in methanol:water 19 
(40:60 v/v) containing 0.1% formic acid and analysed by LC-HRMS. Chromatography was performed 20 
using gradient elution on a Zorbax Eclipse C18 HD 100 mmx2.1 mm, 1.8 µm pore size column with 21 
the column oven temperature at 40˚C. Flow rate of the mobile phase was 0.6ml/min with a run time 22 
of 2.5 min. Electrospray positive ionization was used for MS detection. Drug recoveries from spiked 23 
blood spots were 68% for simvastatin and ≥ 87% for all other target drugs. Compound specificity was 24 
obtained operating the MS with a 5ppm mass window. The LC-HRMS method was validated, with 25 
results for accuracy and precision within acceptable limits; analytes were stable at room 26 
temperature for at least 10 weeks and different blood spot volumes and haematocrit values had no 27 
significant effect. The LC-HRMS assay was used to analyse DBS samples from volunteers, some of 28 
whom were prescribed one or more of the target drugs. In results from 37 volunteers the assay 29 
successfully identified volunteers who were known to be either adherent or nonadherent; confirmed 30 
the correct drug/drugs for multiple prescriptions; demonstrated no false positives from other 31 
cardiovascular drugs; revealed several examples of unsuspected non-adherence. These results 32 
indicated that the developed assay was suitable for trials with patients. 33 
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Cardiovascular disease (CVD) involving disorders of the heart and blood vessels remains the number 40 
one cause of death globally [1]. It affects an estimated 7 million people in the UK and is responsible 41 
for about 155,000 deaths each year. The economic burden of CVD is large with healthcare costs 42 
alone estimated at £11 billion every year in the UK [2]. An essential component of managing 43 
cardiovascular diseases properly and ensuring treatment success is to ensure patients take the 44 
prescribed medication. The drug selected and the dose prescribed should produce therapeutic drug 45 
levels in the patient’s blood stream. Patient adherence to the prescription helps ensure that the 46 
blood concentration of the drug is within the therapeutic limits in order to improve treatment 47 
outcomes [3]. However a World Health Organisation (WHO) report [4] stated that about 50% of all 48 
patients do not adhere to their treatment regimen. Evidence suggests that ˃50% of heart disease 49 
patients do not adhere to their prescription treatment [5]. In the UK, for example, about 370 million 50 
prescriptions were dispensed for heart diseases in 2014 and half of these were believed to be 51 
wasted because patients did not take their medicines as prescribed [6]. According to a National 52 
Institute of Clinical Excellence (NICE) guideline on medication adherence, wasted (unused) medicines 53 
cost the  UK National Health Service (NHS) up to £4 billion annually [7, 8]. This level of non-54 
adherence results in poor clinical outcomes, increased cost of care, hospital readmission, and 55 
sometimes death [9]. 56 
There is currently no gold standard measurement tool for assessing adherence to prescription 57 
medication in routine clinical practice [10]. Current methods to assess medication adherence 58 
involves patient self-report, pill counts, pharmacy refill or claims, data logs or electronic monitors.  59 
None of these can confirm the patient ingested the medication and therefore only capture a part of 60 
the information needed for accurate assessment of medication adherence and consequently may 61 
lead to optimistic results [11, 12]. Sensors are now available that can document ingestion but patient 62 
security and cost may be of concern [13, 14]. 63 
Therapeutic drug levels are conventionally monitored using either whole blood or plasma samples. 64 
Urine samples can only confirm that particular drugs were ingested based on the detection of either 65 
the drug or its metabolite. Urine analysis has been used to investigate the presence of prescribed 66 
CVD drugs for patients exhibiting ‘resistant hypertension’ [15, 16] but this approach provides no 67 
information of the drug levels in the patient’s blood. Data obtained from the routine 10ml liquid 68 
blood samples or the more recently developed dried blood spot (DBS) samples can confirm 69 
satisfactory adherence to medication by confirming a therapeutic level of the drug in the patient’s 70 
blood [17]. In addition, as the population ages and patients are given more prescriptions 71 
(polypharmacy) factors such as individual variation in drug metabolism and possible drug-drug 72 
interactions become more important [18]. Hence monitoring therapeutic drug levels by direct 73 
analyses of patient blood samples can offer clinicians very valuable information about possible drug-74 
drug interactions, side effects occurring from the co-administration of several cardiovascular drugs 75 
[19] and a patient’s adherence to a complex prescribed medication regimen. 76 
The quantitative determination of target cardiovascular drugs in plasma using either liquid 77 
chromatography – tandem mass spectrometry (LC-MS/MS) [20] or LC-MS [21] has been reported. 78 
However, these investigations required large sample volumes (1 – 10ml) of blood which would not 79 




approach to measuring CVD drug concentrations [22] and since it requires only a micro blood 81 
volume (<30µl) it has great potential in overcoming the barriers associated with blood collection 82 
using venepuncture [23]. DBS sample collection can be undertaken by the patients themselves or by 83 
parents/guardians at home. This allows for convenient monitoring at any desired sampling time [24]. 84 
Tanna et al [25-27] have reported the ease of use and low cost of the DBS micro-sampling platform 85 
which makes it ideal for assessing adherence to selected CVD medication.  86 
This article describes a method for fast and simple quantification of ten (10) commonly UK 87 
prescribed cardiovascular drugs from DBS samples using liquid chromatography – high resolution 88 
mass spectrometry (LC-HRMS) analyses. The target drugs studied were atenolol, atorvastatin, 89 
bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril, simvastatin, and valsartan. The 90 
developed and validated method was used to assess adherence to prescribed cardiovascular 91 
medication using blood spot samples taken from volunteers; some prescribed with no medication 92 
and others who were prescribed with one or more of the target drugs investigated. It was envisaged 93 
that this group would provide a challenge to the capabilities of the system developed. 94 
 95 
2. Experimental 96 
2.1 Chemicals and Materials 97 
Reference drug samples: atenolol (R-(+), 99%), atenolol d7, atorvastatin calcium salt, bisoprolol 98 
hemifumarate salt, diltiazem hydrochloride, doxazosin mesylate salt, lisinopril, losartan potassium 99 
salt, ramipril, simvastatin and valsartan were purchased from Sigma–Aldrich (Poole, UK). LC–MS 100 
grade acetonitrile, methanol and water were also obtained from Sigma–Aldrich (Poole, UK). 903 101 
specimen collection paper, polyethylene bags, microcentrifuge tubes (1.5 ml), pipette tips and 102 
volumetric pipettes were purchased from Fisher Scientific (Loughborough, UK). Autosampler vials 103 
with 250µl inserts, vial caps and formic acid were obtained from Agilent Technologies (Cheshire, UK). 104 
Heparin coated blood collection tubes were purchased from International Scientifique Supplies Ltd. 105 
(Bradford, UK). An 8 mm diameter punch was acquired from Maun Industries Ltd. (Nottingham, UK).  106 
Following De Montfort University’s Ethics Protocols, fresh blank blood was obtained from informed 107 
volunteers. 108 
 109 
2.2 Preparation of standard stock and working solutions for the 10 cardiovascular drugs  110 
Atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril, simvastatin and 111 
valsartan standard stock solutions were prepared in methanol at a concentration of 1mg/ml. 112 
Multicomponent working solutions for each target drug were prepared freshly by diluting the stock 113 
solutions with methanol/water (70:30, v/v). 114 
For the preparation of spiked blood standards, several samples of fresh blank blood (900 µl) were 115 
spiked with 100 µl of one of each multicomponent working solution to produce final blood target 116 




was spiked into 900µl of fresh blank blood to produce a zero (blank) blood sample. Internal 118 
standard, atenolol D7 stock solution was prepared in methanol at a concentration of 10µg/ml and 119 
diluted further with methanol/water (70:30, v/v) to produce an extraction solvent containing 20 120 
ng/ml of IS. Whilst it is generally recommended to use 5% solvent when preparing DBS calibration 121 
and quality control (QC) standards, 10% solvent was used in this assay. Work in this laboratory [27, 122 
28] has shown that the use of a 10% solvent standard did not produce any changes to the blood spot 123 
spreading. 124 
 125 
2.3 Preparation of calibration standards and validation samples  126 
The calibration ranges were chosen to cover the concentration ranges in (Table 1) for the selected 127 
drugs. A minimum of 7-point calibration curve was prepared by spotting 30µl of calibration 128 
standards including blanks directly onto the 903 sampling paper using a volumetric pipette.  The 129 
prepared samples were dried at room temperature for at least 3h prior to processing. A 30 µl 130 
volume produced a spot of size of   ̴9.5 mm in diameter on the sampling paper.  131 
2.4 Solvent extraction of analytes from dried blood spot 132 
An 8 mm disc (  ̴20 µl of blood) was punched from the centre of each DBS sample and transferred to 133 
a 1.5 ml micro-centrifuge tube. A 300 µl volume of methanol containing IS (20 ng/ml), atenolol D7, 134 
was used for the extraction of atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, 135 
losartan, ramipril, simvastatin and valsartan because of its optimum extraction efficiency and less 136 
interference. Tubes were vortexed for 1 min, sonicated for 30 mins in a temperature controlled 137 
ultrasonic bath at 40°C and centrifuged at 13200rpm for 10mins. 270 µl of each supernatant was 138 
transferred into a new microcentrifuge tube and dried under a gentle stream of N2 gas. Dried residue 139 
was reconstituted with 150 µl of methanol/water (40:60, v/v) containing 0.1% formic acid. The final 140 
extracts were transferred into auto-sampler vials for LC-HRMS analyses.    141 
2.5 LC-High Resolution MS analyses 142 
Chromatographic and mass spectrometry conditions were optimized for better chromatographic 143 
separation and sensitivity for the 10 cardiovascular drugs. Analyses were performed on an Agilent 144 
1290 LC on-line to an Agilent G6530A QTOF mass spectrometer, operated in the TOF mode with a 5 145 
parts-per-million mass to charge window. Separation of the ten target drugs was achieved using a 146 
Zorbax Eclipse Plus C18 rapid resolution HD column (100 mm x 2.1 mm i.d., 1.8 µm particle pore size) 147 
Agilent Technologies, Cheshire, UK which was preceded by a security guard ultra-cartridge 148 
(Phenomenex, Macclesfield, UK. The LC injector was maintained at 4oC, the injection volume was 20 149 
µl and the column oven was maintained at 40oC. The mobile phases used were water containing 150 
0.1% (v/v) formic acid (eluent A) and acetonitrile containing 0.1% (v/v) formic acid (eluent B) 151 
delivered at a flow rate of 0.6 ml/min with gradient elution. The mobile phase was initiated at 4% B 152 
and held for 0.5 min before increasing to 65% B for 1.0 min and then to 95% B by 1.5 min and 153 
maintained until 2.5 min before returning to 4% B. Column re-equilibration was achieved by holding 154 





The mass spectrometer was operated in electrospray positive ion mode. Calibration of the TOF mass 157 
spectrometer was performed daily before analyses. The optimum MS source and chamber 158 
conditions were: fragmentor voltage: 150 V; skimmer: 65 V; drying gas temperature: 350°C; drying 159 
gas flow: 10 l/min; nebuliser: 45.0 psig; sheath gas temperature: 400°C; sheath gas flow: 12 l/min. 160 
Mass range: 100–1000 m/z; recording rate: 1 Hz. HRMS reference masses: 121.0508 m/z and 161 
922.00979 m/z. MassHunter Workstation Acquisition Software for TOF/Q-TOF version B.04.00 162 
(Agilent Technologies) was used to operate the system and acquire all data. The data was processed 163 
using Qualitative Analysis B.04.00 and Quantitative Analysis B.05.00 SP02 software (Agilent 164 
Technologies). 165 
2.6 Validation studies 166 
For the purposes of validation studies, three concentrations were chosen for the independent 167 
preparation of quality control samples (QCs) at low, medium and high concentration levels for each 168 
target drug and run alongside calibration standards as detailed in Table 2. To demonstrate that the 169 
developed bioanalytical method was fit for purpose, validation was conducted based upon 170 
international guidelines [29, 30]. The selectivity, linearity, sensitivity, intra and inter-assay accuracy 171 
and precision, limit of quantification (LOQ), matrix effects, haematocrit effects and stability were 172 
determined for atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril, 173 
simvastatin and valsartan. 174 
2.6.1 Selectivity 175 
Possible interference from the matrix was investigated by the analyses of blank blood spots and 176 
target analyte spiked blood spots and the data processed. A mass window of 5 ppm was used to 177 
generate extracted ion chromatograms (EIC) for protonated species of atenolol at m/z 267.1703, 178 
atorvastatin at m/z 559.2610, bisoprolol at m/z 326.2326, diltiazem at m/z 415.1686, doxazosin at 179 
m/z 452.1928, lisinopril at m/z 406.2336, losartan at m/z 423.1695, ramipril at m/z 417.2384, and 180 
valsartan at m/z 436.2343. For simvastatin, the sodium adduct ion with a 5 ppm mass extraction 181 
window gave the highest intensity signal at m/z 441.2611 and was used for quantification. 182 
2.6.2 Linearity and sensitivity 183 
Replicate (n = 6) analyses of calibration standards were run per day over the three days. A 184 
calibration plot for each target analyte/IS peak area ratio against nominal analyte concentration was 185 
produced and an equally-weighted linear regression was applied. The limit of quantification of 186 
atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril, simvastatin and 187 
valsartan in the DBS extracts was determined using a signal-to-noise ratio of ≥ 10. The coefficient of 188 
variation at the limit of quantification (LOQ) determined for each target drug (n = 6) was within the 189 
≤20% limit. 190 
2.6.3 Accuracy and precision 191 
Replicate (n = 6) analyses of (QCs) samples at the low, medium and high concentration levels of the 192 
ten target drugs, were analysed to evaluate the inter and intra-day accuracy and precision. Accuracy 193 
was expressed as the relative error (RE%) and precision as the coefficient of variation (CV%). With 194 
reference to FDA and EU guidelines, a RE and CV of ≤15% at all tested concentrations was 195 




2.6.4 Matrix effects 197 
To assess the effect of matrix due to constituents within the dried blood spot, blood samples were 198 
collected from three different sources. Replicate (n = 6) samples of the ten target analytes spiked in 199 
blank blood spot extracts to represent low, medium and high concentrations were prepared to 200 
evaluate suppression or enhancement of the detector response. The prepared samples were 201 
compared with standards of equal concentration spiked into methanol/water (40:60, v/v) containing 202 
0.1% formic acid for atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, 203 
ramipril, simvastatin and valsartan. The matrix effect was calculated using the formula (B/A − 1) x 204 
100. Where A represents the ratio of the target analyte/I.S response from analyte spiked into pure 205 
solvent and B represents the ratio of target analyte/I.S response from analyte spiked into extracted 206 
blank whole blood. 207 
2.6.5 Recovery of the 10 target analytes from dried blood spots 208 
Extraction efficiency was determined using replicate (n = 6) samples prepared at the (low, medium 209 
and high) concentrations for the ten target drugs from spiked DBS. Recovery was assessed by 210 
comparing the ratios of analyte to I.S response from DBS extracts with those obtained from blank 211 
blood spot extracts spiked with solution standards of equal concentration. Recovery was calculated 212 
using the formula: % recovery = (analyte to I.S response of dried blood spot extract/analyte to I.S 213 
response of post extraction blank DBS spiked extract) x 100.  214 
2.6.6 Blood spot size 215 
This investigation was conducted to demonstrate that after selection of a disc size for analyses, the 216 
quantitative results obtained were not affected by the volume of blood deposited or the size of the 217 
blood spot presuming there is uniformity in the spread of the spot on filter paper. To investigate the 218 
blood volume effect on the quantification of the ten target analytes, replicate analyses (n = 6) were 219 
performed at medium and high concentrations for the target drugs using prepared 20, 30 and 40 µl 220 
blood spots. These spots had different diameters directly proportional to sample volume deposited. 221 
8mm discs (approximately 20 µl of blood) were punched from the centre of the already prepared 20, 222 
30 and 40 µl volume DBS standards. Extraction of the target drugs was performed using the 223 
procedure described in Section 2.4 prior to LC-HRMS analyses. Using a linear regression equation 224 
obtained from a calibration generated with 30 µl volume DBS, the analyte concentration of the 225 
extracts were determined. 226 
2.6.7 Evaluation of Haematocrit effects 227 
The haematocrit (Hct) level represents the relative volume of red blood cells (RBC) in blood. It has a 228 
direct effect on the viscosity of blood, which in turn affects the spread of blood on cellulose based 229 
paper. Hence permeability of a DBS card is influenced by the haematocrit of blood [31, 32]. Blood 230 
with high Hct (due to the high cellular composition) is more viscous and leads to the formation of 231 
small spots on DBS cards. The Hct range varies according to age for healthy adult males and females. 232 
It is 40 – 54% and 36 – 48% respectively [33]. Hct values may however deviate from these ranges in 233 
certain disease states e.g. anaemia and polycythaemia. An Hct value of 45% was chosen to represent 234 
the average value expected in the target population planned for this study. The bias caused by the 235 




quantitative DBS analyses [34, 35]. Hence the influence of haematocrit on assay performance was 237 
evaluated at the low, medium and high concentrations of each target drug (n = 6) using 30µl spots 238 
with an adjusted Hct of 35, 45 and 55% to cover the range for the target population.  239 
 240 
 241 
2.6.7.1 Preparation of DBS with adjusted Hct of 35, 45 and 55% 242 
Blank human whole blood was centrifuged at 10,000g for 12 minutes [36, 37]. The plasma generated 243 
was transferred into a clean eppendorf tube. The RBC suspension and plasma were mixed in 244 
proportions (35:65, v/v), (45:55, v/v) and (55:45, v/v) to give whole blood with an adjusted Hct of 35, 245 
45 and 55% respectively. These were used to prepare calibration DBS samples for the ten target 246 
analytes at the blank, low, medium and high concentration ranges. 30µl of each prepared standard 247 
were spotted on 903 sampling papers and allowed to dry for 3 hours. 8mm disc were punched from 248 
the centre of each spot and extracted using the procedure described in section 2.4. 249 
2.6.8 Stability of dried blood spots 250 
Stability experiments were performed for the DBS samples during storage at room temperature for 251 
10 weeks, demonstrating the possibility to prepare DBS samples in batches followed by storage. This 252 
was done by the replicate analyses (n = 6) of blood spots containing atenolol, atorvastatin, 253 
bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril, simvastatin and valsartan at the low, 254 
medium and high concentrations. Using the extraction procedure described in Section 2.4, 8mm 255 
diameter discs were punched from the DBS calibration standards at the low, medium and high 256 
concentrations of the 10 target drugs and analysed. 257 
2.7 Application of method to volunteer blood spot samples 258 
The developed DBS based LC–HRMS method was applied to a series of dried blood spot samples 259 
collected from selected healthy volunteers. These volunteers were all prescribed with one or more 260 
of the target drugs atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, 261 
ramipril, simvastatin and valsartan. Samples were taken between 0.5 and 24 h after the oral intake 262 
of the drugs. A series of blank control DBS samples were taken from a second group of volunteers 263 
not prescribed any of the target drugs. The study has received ethical approval from the De 264 


























Figure 1. Representative LC-HRMS extracted ion chromatograms of an extracted blank blood spot 285 
(red) and a calibration standard at the LOQ spiked with the ten target drugs (black). A narrow mass 286 
extraction window (5ppm) was used for (a) atenolol at m/z 267.1703 (b) atorvastatin at m/z 287 
559.2610 (c) bisoprolol at m/z 326.2326 (d) diltiazem at m/z 415.1686 (e) doxazosin at m/z 452.1928 288 
(f) lisinopril at m/z 406.2336 (g) losartan at m/z 423.1695 (h) ramipril at m/z 417.2384 (i) simvastatin 289 






Table 1  
Linearity and sensitivity data for the ten cardiovascular drugs 
Drug Range (ng/ml) y = ax + b R2 LOQ (ng/ml) 
Atenolol 10 - 1500 y = 0.0044x - 0.047 0.997 ± 0.001 10 
Atorvastatin 0.5 - 100 y = 0.0014x + 0.0244 0.986 ± 0.013 0.5 
Bisoprolol 0.1 - 100 y = 0.019x + 0.034 0.994 ± 0.003 0.1 
Diltiazem 0.5 - 600 y = 0.016x + 0.053 0.997 ± 0.002 0.5 
Doxazosin 0.1 - 100 y = 0.016x + 0.033 0.992 ± 0.005 0.1 
Lisinopril 0.1 - 100 y = 0.002x + 0.031 0.978 ± 0.007 0.1 
Losartan 5 - 1000 y = 0.004x + 0.0713 0.995 ± 0.002 5 
Ramipril 0.1 - 100 y = 0.025x + 0.018 0.997 ± 0.002 0.1 
Simvastatin 0.1 - 100 y  = 0.013x + 0.081 0.996 ± 0.003 0.1 























Table 2  
Intra and inter-day accuracy and precision data for the ten target cardiovascular drugs in DBS samples 
(n = 6 at all concentration levels, for 3 days) 
      Coefficient of variation (%) 
Drug Nominal conc. (ng/ml) Measured conc. (ng/ml) Intra day Inter day 
Atenolol 50 51.87 4.00 1.37 
 
500 498.02 4.14 1.36 
 
1500 1517.51 2.22 1.24 
Atorvastatin 1 1.05 4.06 5.93 
 
25 25.23 7.54 2.45 
 
100 100.69 7.19 2.41 
Bisoprolol 1 1.09 2.63 3.50 
 
25 25.54 6.10 4.14 
 
100 102.42 3.21 2.76 
Diltiazem 5 5.29 5.95 0.83 
 
100 98.64 6.41 1.06 
 
600 611.85 2.03 1.49 
Doxazosin 1 1.07 9.23 1.03 
 
25 25.59 3.74 3.58 
 
100 99.24 3.89 2.78 
Lisinopril 1 1.04 9.14 1.37 
 
25 24.91 6.55 1.89 
 
100 100.31 6.61 2.19 
Losartan 25 25.25 3.08 0.54 
 
250 248.57 5.03 0.59 
 
1000 1014.66 5.99 1.62 
Ramipril 1 1.01 4.29 2.60 
 
25 25.23 6.17 2.92 
 
100 101.76 4.60 3.28 
Simvastatin 1 1.06 10.01 6.81 
 
25 25.13 6.43 0.86 
 
100 99.85 3.98 2.11 
Valsartan 250 242.75 3.71 1.44 
 
2000 2078.29 3.32 3.44 











Table 3  
Matrix effect results obtained for the ten target drugs studied at the low, medium and high 
concentration levels. (n = 6 for each concentration). 
Drug Nominal conc. (ng/ml) Matrix effect % (mean) Precision (CV%) 
Atenolol 50 -1.94 5.59 
 
500 0.84 2.03 
 
1500 -1.86 1.72 
Atorvastatin 1 2.41 1.65 
 
25 1.25 1.93 
 
100 1.95 1.29 
Bisoprolol 1 -1.39 2.17 
 
25 0.41 2.73 
 
100 0.67 0.98 
Diltiazem 5 1.43 2.75 
 
100 0.06 3.03 
 
600 1.49 1.33 
Doxazosin 1 0.60 2.76 
 
25 0.73 1.69 
 
100 -0.85 2.01 
Lisinopril 1 8.91 4.55 
 
25 5.99 1.60 
 
100 2.54 2.33 
Losartan 25 0.94 1.72 
 
250 2.07 1.51 
 
1000 0.51 0.93 
Ramipril 1 0.35 2.86 
 
25 0.54 2.94 
 
100 1.98 0.34 
Simvastatin 1 7.01 6.23 
 
25 -3.62 5.43 
 
100 -4.56 5.68 
Valsartan 250 -1.12 2.71 
 
2000 -1.70 2.97 












Recovery data for the 10 target drugs extracted from DBS at the low, medium and high concentration 
levels (n = 6). 
Drug Nominal conc. (ng/ml) Recovery (%) Standard Deviation (SD) Precision (CV%) 
Atenolol 50 89.13 6.53 7.32 
 
500 82.54 7.60 9.21 
 
1500 93.16 3.69 3.96 
Atorvastatin 1 101.09 10.24 10.13 
 
25 95.43 7.25 7.60 
 
100 99.76 1.64 1.64 
Bisoprolol 1 101.65 11.34 11.16 
 
25 99.19 5.68 5.73 
 
100 89.53 5.52 6.16 
Diltiazem 5 98.08 12.42 12.67 
 
100 88.92 4.24 4.77 
 
600 85.05 1.80 2.11 
Doxazosin 1 97.86 7.07 7.23 
 
25 97.37 5.00 5.14 
 
100 94.89 6.19 6.52 
Lisinopril 1 97.43 9.08 9.32 
 
25 90.51 7.88 8.71 
 
100 75.39 4.65 6.17 
Losartan 25 97.34 4.03 4.14 
 
250 94.27 10.25 10.88 
 
1000 87.1 4.61 5.30 
Ramipril 1 97.08 7.15 7.37 
 
25 89.94 5.38 5.98 
 
100 92.96 3.36 3.62 
Simvastatin 1 67.88 4.26 6.28 
 
25 64.74 5.97 9.22 
 
100 70.81 3.96 5.59 
Valsartan 250 100.66 3.44 3.41 
 
2000 97.35 2.29 2.35 













Impact of dried blood spot size on accuracy and precision of assay at the medium and high concentrations for 
each target drug (n = 6) 




Mean concentration found 





500 40 523.84 ± 9.03 4.77 1.72 
 
30 489.10 ± 19.27 2.18 3.94 
 
20 494.26 ± 17.82 1.15 3.61 
     1500 40 1492.36 ± 129.02 0.51 8.65 
 
30 1456.05 ± 12.75 2.93 0.88 
 
20 1590.79 ± 16.73 6.05 1.05 
     Atorvastatin concentration in 
whole blood (ng/ml) 
DBS volume 
(µl) 
Mean concentration found 





25 40 24.33 ± 2.25 2.26 9.24 
 
30 24.55 ± 2.06 1.81 8.39 
 
20 24.80 ± 3.11 0.79 12.54 
     100 40 100.94 ± 3.90 0.94 3.86 
 
30 98.32 ± 2.83 1.68 2.88 
 
20 100.35 ± 2.75 0.35 2.74 
     Bisoprolol concentration in 
whole blood (ng/ml) 
DBS volume 
(µl) 
Mean concentration found 





25 40 25.41 ± 2.62 1.65 10.33 
 
30 22.96 ± 0.71 8.17 3.07 
 
20 25.25 ± 1.07 0.99 4.22 
     100 40 99.93 ± 1.41 0.07 1.42 
 
30 101.52 ± 7.10 1.52 6.99 
 
20 105.27 ± 2.95 5.27 2.8 
     Diltiazem concentration in 
whole blood (ng/ml) 
DBS volume 
(µl) 
Mean concentration found 





100 40 92.51 ± 5.40 7.49 5.84 
 
30 93.18 ± 6.23 6.82 6.69 
 
20 91.70 ± 5.59 8.3 6.1 
     600 40 595.19 ± 34.09 0.8 5.73 
 
30 590.04 ± 10.84 1.66 1.84 
 
20 615.61 ± 4.35 2.6 0.71 
     Doxazosin concentration in 
whole blood (ng/ml) 
DBS volume 
(µl) 
Mean concentration found 





25 40 25.37 ± 1.19 1.46 4.68 
 
30 26.26 ± 0.96 5.03 3.64 
 
20 25.71 ± 1.04 2.83 4.05 
     100 40 100.77 ± 5.74 0.77 5.69 
 
30 98.96 ± 2.17 1.04 2.2 
 





Table 5 continued 




Mean concentration found 





25 40 24.01 ± 1.02 3.96 4.27 
 
30 26.47 ± 2.39 5.87 9.04 
 
20 25.81 ± 2.18 3.25 8.44 
     100 40 102.00 ± 7.91 2 7.75 
 
30 100.21 ± 5.04 0.21 5.03 
 
20 107.93 ± 3.41 7.93 3.16 




Mean concentration found 





250 40 251.40 ± 3.90 0.56 1.55 
 
30 251.87 ± 2.51 0.75 1 
 
20 250.16 ± 6.41 0.07 2.56 
     1000 40 1012.38 ± 43.75 1.24 4.32 
 
30 987.23 ± 20.32 1.28 2.06 
 
20 1017.71 ± 14.84 1.77 1.46 




Mean concentration found 





25 40 24.80 ± 1.06 0.81 4.26 
 
30 25.84 ± 0.95 3.36 3.69 
 
20 24.67 ± 0.82 1.33 3.31 
     100 40 101.18 ± 4.86 1.18 4.81 
 
30 99.59 ± 1.09 0.41 1.1 
 
20 102.95 ± 2.18 2.95 2.12 
     Simvastatin concentration in 
whole blood (ng/ml) 
DBS volume 
(µl) 
Mean concentration found 





25 40 25.46 ± 1.77 1.82 6.95 
 
30 25.57 ± 0.88 2.27 3.44 
 
20 25.14 ± 0.54 0.58 2.16 
     100 40 105.55 ± 6.18 5.55 5.86 
 
30 100.84 ± 3.11 0.84 3.08 
 
20 100.91 ± 1.87 0.91 1.86 
     Valsartan concentration in 
whole blood (ng/ml) 
DBS volume 
(µl) 
Mean concentration found 





2000 40 1942.50 ± 17.02 2.87 0.88 
 
30 1943.26 ± 11.80 2.84 0.61 
 
20 1988.18 ± 83.18 0.59 4.18 
     4000 40 4038.38 ± 77.57 0.96 1.92 
 
30 4075.53 ± 83.71 1.89 2.05 
 






Table 6  
Influence of Haematocrit on the accuracy (RE %) of analyte quantification presented as the difference from the 
analyte/internal standard peak area ratio at the 45% Hct level. Precision (CV %) values for each tested 
concentration are shown in brackets (n = 6). 
    Haematocrit 
Drug Concentration (ng/ml) 35% 45% (Normalized) 55% 
Atenolol 50 -7.4% (4.1%)  (5.9%) 8.8% (3.5%) 
 
500 -7.6% (1.5%) (2.6%) 14.5% (5.0%) 
 
1500 -8.4% (3.6%) (1.9%) 6.4% (2.1%) 
Atorvastatin 1 -4.1% (6.04%) (10.1%) -4.0% (12.8%) 
 
25 -15.3% (2.67%) (6.6%) 12.5% (7.7%) 
 
100 -14.6% (3.65%) (3.0%) -2.2% (2.6%) 
Bisoprolol 1 -10.2% (9.2%) (5.1%) 11.2% (10.5%) 
 
25 -12.4% (4.6%) (15.1%) 13.8% (5.5%) 
 
100 -14.4% (7.3%) (7.0%) 7.9% (4.7%) 
Diltiazem 5 -9.4% (6.3%) (10.1%) 13.1% (5.5%) 
 
100 -7.1% (10.6%) (6.6%) 13.9% (2.8%) 
 
600 -12.3% (2.4%) (3.0%) 10.5% (1.5%) 
Doxazosin 1 -14.1% (5.2%) (10.3%) 3.1% (7.8%) 
 
25 -3.0% (4.6%) (3.9%) 2.8% (2.1%) 
 
100 -7.9% (4.2%) (5.5%) 5.7% (3.3%) 
Lisinopril 1 -10.7% (10.3%) (10.1%) 8.5% (6.1%) 
 
25 -12.8% (4.7%) (6.6%) 3.4% (8.7%) 
 
100 -6.6% (10.5%) (3.0%) 10.3% (10.1%) 
Losartan 25 -14.3% (7.0%) (5.0%) 7.14% (6.6%) 
 
250 -9.8% (2.2%) (7.9%) 10.9% (6.0%) 
 
1000 -9.3% (5.6%) (6.1%) 2.7% (1.9%) 
Ramipril 1 -10.6% (14.2%) (6.1%) 12.8% (7.8%) 
 
25 -10.1% (4.1%) (5.9%) 7.2% (6.2%) 
 
100 -9.1% (1.7%) (6.2%) 1.4% (1.37%) 
Simvastatin 1 1.5% (12.3%) (10.1%) (-13.4%) (3.8%) 
 
25 -13.3% (6.0%) (6.6%) 11.5% (7.4%) 
 
100 -3.1% (2.9%) (3.0%) 9.5% (8.9%) 
Valsartan 250 -11.5% (5.5%) (1.6%) -5.4% (8.2%) 
 
2000 -7.6% (7.2%) (8.2%) 13.6% (11.5%) 











Accuracy,  precision and  quantification of DBS assay  at the low, medium and high concentrations for each 
target drug after 10 weeks of storage at room temperature (n = 6) 
Drug Concentration in whole 
blood (ng/ml) 
Mean concentration found 
(ng/ml) (n=6) 
Accuracy (RE%) Precision (CV%) 
Atenolol 50 59.9 12.06 1.11 
 
500 464.47 0.52 2.58 
 
1500 1572.7 -0.69 0.85 
Atorvastatin 1 1.2 -1.34 11.69 
 
25 27.64 0.17 8.34 
 
100 91.51 -1.58 2.10 
Bisoprolol 1 1.19 4.77 9.57 
 
25 28.21 -2.13 2.68 
 
100 116.01 4.50 5.74 
Diltiazem 5 4.7 4.51 4.68 
 
100 109.97 1.93 5.64 
 
600 631.98 -3.95 2.64 
Doxazosin 1 1.11 10.74 6.68 
 
25 27.93 3.47 5.52 
 
100 100.45 -0.50 0.61 
Lisinopril 1 1.13 13.0 9.01 
 
25 29.13 3.46 6.71 
 
100 106.95 -2.06 4.21 
Losartan 25 23.9 4.40 7.93 
 
250 259.25 -0.47 2.85 
 
1000 1111.52 1.66 0.91 
Ramipril 1 1.12 12.41 3.66 
 
25 21.33 5.12 2.09 
 
100 94.96 2.28 3.13 
Simvastatin 1 1.2 4.30 5.45 
 
25 23.62 -0.89 3.00 
 
100 95.28 -1.09 2.70 
Valsartan 250 242.62 -0.85 6.47 
 
2000 1972.39 7.35 8.62 












DBS concentrations of the studied cardiovascular drugs from volunteers prescribed with one or more of the 
CVD drugs investigated. 





1 M Bisoprolol 2mg 4 41.78 ± 1.99 37 - 87 
 
 
Doxazosin 4mg 4 32.74 ± 1.04 18 - 48 
 
 
Valsartan 160mg 4 493.72 ± 8.78 879 - 3874 
2 M Atorvastatin 10mg 11 8.88 ± 0.99 3.2 -10.5 
  
Losartan 50mg 11 28.95 ± 1.93 89 - 306 
3 F Losartan 75mg 22 20.60 ± 5.65 263 - 783 
4 F Simvastatin 20mg 13 2.90 ± 0.77 5.1 - 40.1 
5 F Ramipril 1.25mg 5 3.11 ± 0.37 <11.1 - 31.1 
6 F Losartan 100mg 5.5 11.60 ± 1.51 469 - 1131 
7 M Losartan 5mg  7 6.25 ± 3.41 89 -306 
8 M Atorvastatin (lowest) 16 6.11 ± 2.21 3.2 -10.5 
9 F Atorvastatin 20mg 17 6.77 ± 3.84 5.0 -20.5 
10 M Ramipril 5mg 15 5.22 ± 0.31 <11.1 - 31.1 
  
Simvastatin 20mg 15 1.79±0.74 5.1 - 40.1 
11 M Atorvastatin 10mg 14 5.21±1.99 3.2 -10.5 
12 M Bisoprolol 2mg 4 34.32±12.87 37 - 87 
  
Doxazosin 4mg 4 32.40±2.13 18 - 48 
  
Valsartan 160mg 4 407.16±14.73 879 - 3874 
13 M Simvastatin 11 0.85±0.55 5.1 - 40.1 
  
Ramipril 10mg 2.5 9.37±1.04 11.1 - 31.1 
14 F Atorvastatin 10mg 17 2.86±1.72 3.2 -10.5 
  
Losartan 100mg 7 65.48±3.72 469 - 1131 
15 F Losartan 100mg 6 74.76±8.03 469 - 1131 
16 M Atenolol 50mg 6 456.01±23.20 240 - 1370 
  
Simvastatin 40mg 6 ˂LOQ 5.1 - 40.1 
17 F Ramipril 10mg 18 ˂LOQ 11.1 - 31.1 
18 F Atorvastatin 20mg 14 14.01±2.39 5.0 -20.5 
  
Bisoprolol 5mg 3 23.58±1.94 37 - 87 
19 M Lisinopril 20mg ? 37.02±8.59 50 - 88 
20 M Ramipril 10mg 4 5.29±0.84 11.1 - 31.1 
  
Simvastatin 20mg 10 1.32±0.42 5.1 - 40.1 
21 F Ramipril 5mg 2.5 5.63±0.54 <11.1 - 31.1 
22 M Atorvastatin 40mg > 48 ˂LOQ 13.2 -44.3 
  
Lisinopril 2.5mg 3.5 8.02±3.68 <50 - 88 
23 F Losartan 12.5mg 12 37.57±2.54 43.6 - 125.4 
24 F Bisoprolol 1.25mg 0.3 9.28±0.55 17 - 87 
25 F Ramipril 10mg 4 7.03±0.39 11.1 - 31.1 
26 F Ramipril 2.5mg 3 6.49±0.96 <11.1 - 31.1 
27 F Atorvastatin 40mg 15 18.36±7.20 13.2 - 44.3 
  
Bisoprolol 5mg 8 24.46±5.70 37 - 87 
28-32 F None - Controls N/A ˂LOQ 







3.1 Selectivity 353 
Using the accurate masses determined for the 10 cardiovascular drugs and internal standard, 354 
selectivity was evaluated by comparing extracted ion chromatograms (EICs) derived at the limit of 355 
quantification from a DBS calibration standard for each target analyte and the internal standard with 356 
those obtained from blank DBS samples. A narrow mass extraction window of 5ppm was used to 357 
obtain enhanced selectivity. Representative EICs at the LOQ for each analyte and internal standard is 358 
shown in Figure 1(a) – (k). The protonated molecule [M+H]+ gave a high response for atenolol at m/z 359 
267.1703, atorvastatin at m/z 559.2610, bisoprolol at m/z 326.2326, diltiazem at m/z 415.1686, 360 
doxazosin at m/z 452.1928, lisinopril at m/z 406.2336, losartan at m/z 423.1695, ramipril at m/z 361 
417.2384, and valsartan at m/z 436.2343. The sodium adduct ion [M+Na]+ showed the highest signal 362 
intensity for simvastatin at m/z 441.2611. The DBS based LC-HRMS method showed good selectivity 363 
because the EICs revealed that no interfering peaks were observed at the retention times for each of 364 
the ten drugs and IS. 365 
3.2 Linearity and sensitivity 366 
The calibration curves for the ten target analytes were generated in replicate (n = 6) using a plot of 367 
target analyte/IS peak area ratio against nominal analyte concentration. An equally weighted linear 368 
regression was applied. Back calculations gave relative errors less than 15% (typically between 2 and 369 
10% over the appropriate calibration range for each drug. The data (slope, intercept and the mean 370 
correlation coefficient R2) for each drug is presented in Table 1. The limit of quantification (LOQ) 371 
with a signal to noise ratio of ≥10 and the required assay accuracy and precision was 10ng/ml for 372 
atenolol, 0.5ng/ml for atorvastatin, 0.1ng/ml for bisoprolol, 0.5ng/ml for diltiazem, 0.1ng/ml for 373 
doxazosin, 0.1ng/ml for lisinopril, 5ng/ml for losartan, 0.1ng/ml for ramipril, 0.1ng/ml for 374 
simvastatin, 50ng/ml for valsartan.  375 
3.3 Accuracy and precision 376 
The accuracy and precision of the developed LC-HRMS method were determined by intra and inter-377 
day replicate analyses of six spiked DBS (QC) samples containing the 10 target analytes at the low, 378 
medium and high concentration levels on three separate days. Accuracy was expressed as the mean 379 
relative error (RE %) and precision was expressed as the coefficient of variation (CV %) and data 380 
obtained for both were within the predefined 15% limit for all concentrations in each run for all the 381 
target drugs. The overall variation in data between runs was also ≤15% for all target drugs. A 382 
summary of the results is presented in Table 2. 383 
3.4 Matrix effect 384 
The effect of matrix arising from ionization competition between analytes of interest and co-eluents 385 
[38] was examined to ensure that the sensitivity and precision of the developed method was not 386 
compromised. The matrix effect data obtained for each target analyte investigated at the low, 387 
medium and high concentration levels of the calibration curve is presented in Table 3. No significant 388 
(<10%) matrix effects on the analyte signal due to endogenous components of blood or the sampling 389 
paper was observed at the three tested concentrations of each target drug. These results 390 




target analytes. The introduction of several compounds as I.S could also lead to ionization 392 
competition with the analytes of interest at the ESI source resulting in additional matrix effects.  393 
3.5 Recovery 394 
The extraction recoveries of the ten target analytes from DBS samples at the low, medium and high 395 
concentration levels of the calibration curve were obtained. Recoveries for atenolol, atorvastatin, 396 
bisoprolol, diltiazem, doxazosin, losartan, ramipril and valsartan were consistent, with values 397 
between 87 and 98%. The high recoveries observed indicate analyte stability under the extraction 398 
conditions applied and good extraction. The overall mean recovery for simvastatin was the lowest at 399 
68%. Recovery data for each target analyte at the low, medium and high concentration levels is 400 
summarised in Table 4.  401 
3.6 Blood spot size 402 
Method precision and accuracy were assessed using extraction data from an 8 mm discs, sampled 403 
from the centre of the 20, 30 and 40 µl volume DBS prepared at the medium and high concentration 404 
levels for the ten target analytes. Table 5 shows the intra-day precision and accuracy of the method 405 
evaluated using 6 determinations for each concentration level. Results obtained for accuracy and 406 
precision were less than 15% and therefore considered acceptable. These experiments were 407 
performed to demonstrate that results obtained were not dependent on the size of the blood spot 408 
collected. Analysing a fixed sample size disc should produce extract data which is directly 409 
proportional to the concentration of the target analyte in the original blood sample assuming that 410 
each blood spot will spread evenly and uniformly across the sampling card. The results in Table 5 411 
affirm that within experimental error for each concentration range the data from 8 mm discs is the 412 
same regardless of sample volume chosen. 413 
3.7 Haematocrit (Hct) evaluation 414 
Concentrations of extracts were determined using a linear regression equation generated from a 415 
calibration produced from standards prepared with the 45% Hct. A decrease in size of spots formed 416 
was observed with increasing Hct value across the range of 35% to 55% investigated. The results 417 
from the haematocrit investigation, shown in Table 6, gave accuracy (RE%) and precision (CV%) 418 
values within the pre-defined limit of ≤ 15% [32] at all haematocrit levels for each tested analyte 419 
concentration, except for atorvastatin at the 35% Hct where accuracy was 15.3%. This demonstrates 420 
the acceptability of the developed DBS based LC-HRMS method for quantitative analyses. The results 421 
also demonstrate the robustness of the extraction procedure, as different haematocrits do not result 422 
in differences in matrix effects. 423 
3.8 Stability 424 
The stability of dried blood spot samples after 10 weeks of storage at room temperature was 425 
determined by analysing blood spots prepared at the low, medium and high concentration levels for 426 
the ten target drugs. No significant changes in concentrations were observed at the low, medium 427 
and high concentration levels of target drugs as shown in Table 7. These results demonstrate that for 428 
spiked samples the ten target drugs are stable in DBS for 2 and half months when stored at room 429 
temperature. Studies in this laboratory have shown similar stability for atenolol, bisoprolol, 430 




DBS microsampling methodology in resource limited areas for example Africa. This is because 432 
samples may have to be collected in remote areas of the country and will take several days to be 433 
transported back to the laboratory for analyses.  434 
 435 
3.9 Application of method to volunteer DBS samples 436 
Volunteers were chosen either because they were prescribed one or more of the target medications 437 
or they were receiving no medication at all.  DBS samples from volunteers not prescribed any of the 438 
target drugs were analysed and used as blank reference samples. DBS samples were obtained from 439 
each volunteer by gently massaging the fingertip to encourage blood flow. The finger was pricked 440 
with a retractable lancet and the first drop of blood wiped away with a sterile gauze. Subsequent 441 
drops were deposited onto marked sections on a Whatman 903 sampling card and allowed to dry. 442 
The spot sizes were sufficient to allow the use of an 8mm punch without compromising the DBS 443 
sample. Samples of smaller spot sizes were rejected. The validated DBS based LC-HRMS method was 444 
successfully used for the identification and quantification of 10 target cardiovascular drugs in 146 445 
dried blood spot samples obtained from a group of volunteers. No false signals were detected from 446 
DBS samples from volunteers receiving no medication. Where adherent volunteer samples were 447 
analysed the anticipated drug was detected. Furthermore there were no false positive signals for 448 
volunteers taking chemically related drugs, for example, atenolol and bisoprolol.   449 
The measured DBS drug concentrations obtained are presented in Table 8. The eclectic Cmax data 450 
from the literature for the individual drugs has also been included in Table 8 to provide reference 451 
values against which volunteer data can be compared. Values similar to, but lower than, the Cmax 452 
concentration would be anticipated from volunteers who are adherent to prescribed medication. On 453 
this basis the data in Table 8 would suggest that concern might be raised over the results from: 454 
 volunteer 16 - where atenolol was detected but there was no detectable simvastatin  455 
 volunteer 17 – no detectable ramipril signal 456 
 volunteer 22 - no detectable atorvastatin signal but the anticipated lisinopril was detected 457 
Data from volunteer 16 raised concern initially because both drugs were stated to have been taken 458 
at the same time whereas simvastatin should be taken in the evening. It may be that the patient was 459 
distracted and took two atenolol tablets  rather than one simvastatin tablet. This would lead to a 460 
DBS atenolol level corresponding to a 100mg dose as actually observed by the correlation between 461 
the measured concentration and the Cmax data for a 100mg dose [39]. Non detectable simvastatin 462 
suggests that the patient was non-adherent bearing in mind that volunteers 4, 10 and 20 took 463 
simvastatin at a lower dose of 20mg and which was still detected after 10 hours. Data from 464 
volunteer 17 showed no detectable level of ramipril, the prescribed drug but, according to the 465 
volunteer, the sample was collected 18 hours after the dose was taken and might not be detectable. 466 
In this case the dose was 10mg and as can be seen for volunteer 10, prescribed a 5mg dose, levels of 467 
ramipril were detected 15 hours after taking a dose. This would suggest that volunteer 17 needs to 468 
discuss this situation with the clinician and it should be remembered that pharmacogenetics effects 469 
may lead to unexpected changes in drug levels in the blood. Several studies have demonstrated a 470 
significant link between angiotensin converting enzyme (ACE) gene insertion/deletion (I/D) 471 
polymorphism and cardiovascular outcomes. However, the impact of this genetic polymorphism on 472 




When asked about the data obtained volunteer 22 freely admitted not taking atorvastatin tablets for 474 
several days and was clearly non-adherent to the prescribed medication. These results clearly 475 
indicate areas where a clinician would be unaware of an adverse clinical condition which they would 476 
be able to rectify to improve the individuals healthcare. This also demonstrates the robustness of 477 
the developed DBS based LC-HRMS method. This approach can also identify the situation where a 478 
dose is taken because a test is anticipated (white coat syndrome). This is comparable to a single dose 479 
trial and the pharmacokinetics would lead to a rapid increase followed by a decrease in the drug 480 
concentration in the blood, rather than a steady state situation. A comparison of drug 481 
concentrations in two DBS samples collected several hours apart, from the same volunteer, would 482 
clarify the situation. Significantly less in the second sample would indicate that the dose was taken in 483 
anticipation of the test whereas a comparable level is indicative of a steady state as a result of 484 
adherence to prescription.  485 
 486 
4. Conclusion 487 
The developed and validated DBS based LC–HRMS method offers fast analyses time and the 488 
sensitivity required for the determination of the ten cardiovascular drugs in DBS samples. The 489 
method gave accuracy (RE) and precision (CV) values of ≤ 15% at all tested concentrations for the 490 
ten target drugs. Stability of the ten analytes in DBS following storage at room temperature was 491 
shown to be 10 weeks. This offers the possibility of batch wise preparation and also allows time for 492 
the transportation of samples from remote or resource limited areas to the laboratory for analyses. 493 
Haematocrit effects was observed but was not significant as accuracy (RE%) and precision (CV%) 494 
values obtained were with ≤ 15% limit at all haematocrit levels for each tested analyte 495 
concentration. The method has great potential in aiding clinicians indicate adherence to prescribed 496 
medication to enable treatment to be optimised for patients. The method is currently being 497 
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